ASCO GI 2022Конференция
Доклады:
-
2022
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
(Устный)
-
Авторы:
Abou-Alfa Ghassan K.,
Chan Stephen Lam,
Kudo Masatoshi,
Lau George,
Kelley Robin Kate,
Furuse Junji,
Sukeepaisarnjaroen Wattana,
Kang Yoon-Koo,
Dao Tu V.,
De Toni Enrico N.,
Rimassa Lorenza,
Breder Valeriy Vladimirovich,
Vasilyev Alexander,
Heurgue Alexandra,
Tam Vincent,
Mody Kabir,
Thungappa Satheesh Chiradoni,
He Philip,
Negro Alejandra,
Sangro Bruno